Frank U, Mutter J, Schmidt-Eisenlohr E, Daschner F D
Institute of Environmental Medicine and Hospital Epidemiology, Freiburg University Hospital, Hugstetter Strasse 55, D-79106 Freiburg I.Br., Germany.
Clin Microbiol Infect. 2003 Nov;9(11):1128-32. doi: 10.1046/j.1469-0691.2003.00786.x.
We investigated the antimicrobial activity of piperacillin-tazobactam versus piperacillin-sulbactam against common nosocomial pathogens (n = 565) isolated from intensive care patients. For Gram-positive bacteria, antimicrobial susceptibilities to the two piperacillin-beta-lactamase inhibitor combinations were almost identical. For Gram-negative bacteria, piperacillin-tazobactam exhibited greater activity against Escherichia coli and Proteus vulgaris than piperacillin-sulbactam. Both combinations, however, were equally effective against the other Enterobacteriaceae and Pseudomonas aeruginosa isolates. Piperacillin-sulbactam exhibited better antimicrobial activity against Acinetobacter baumannii. Our findings might prove important for the appropriate choice of antibiotic therapy with beta-lactam-beta-lactamase inhibitor combinations.
我们研究了哌拉西林-他唑巴坦与哌拉西林-舒巴坦对从重症监护患者中分离出的常见医院病原体(n = 565)的抗菌活性。对于革兰氏阳性菌,两种哌拉西林-β-内酰胺酶抑制剂组合的抗菌敏感性几乎相同。对于革兰氏阴性菌,哌拉西林-他唑巴坦对大肠杆菌和普通变形杆菌的活性比哌拉西林-舒巴坦更强。然而,两种组合对其他肠杆菌科细菌和铜绿假单胞菌分离株的效果相同。哌拉西林-舒巴坦对鲍曼不动杆菌表现出更好的抗菌活性。我们的研究结果可能对β-内酰胺-β-内酰胺酶抑制剂组合抗生素治疗的合理选择具有重要意义。